# Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment

> **NCT04776096** · PHASE4 · COMPLETED · sponsor: **Laboratorios Poen** · enrollment: 97 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** Bepotastine Besilate 1.5% PF
- **DRUG:** Olopatadine Hydrochloride 0.2% BAK

## Key facts

- **NCT ID:** NCT04776096
- **Lead sponsor:** Laboratorios Poen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-10
- **Primary completion:** 2022-08-18
- **Final completion:** 2022-08-18
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2022-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04776096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04776096, "Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04776096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*